Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Merck (Antagonist Compound)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

An antagonist compound formula. The formula is used to produce chemicals and medicines to treat insomnia and potentially other central nervous system (CNS) disorders.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Acquirer
Primary Office
  • Frankfurter Straße 250
  • 64293 Darmstadt
  • Germany

Merck (Antagonist Compound) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Merck (Antagonist Compound)‘s full profile, request access.

Request full access to PitchBook

Merck (Antagonist Compound) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Merck (Antagonist Compound)‘s full profile, request access.

Request full access to PitchBook